Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences
An increasing amount of findings suggests that the aggregation of soluble peptides and proteins into amyloid fibrils is a relevant upstream process in the complex cascade of events leading to the pathology of Alzheimer's disease and several other neurodegenerative disorders. Nevertheless, sever...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical research 2017-12, Vol.34 (12), p.2628-2636 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2636 |
|---|---|
| container_issue | 12 |
| container_start_page | 2628 |
| container_title | Pharmaceutical research |
| container_volume | 34 |
| creator | Arosio, Paolo |
| description | An increasing amount of findings suggests that the aggregation of soluble peptides and proteins into amyloid fibrils is a relevant upstream process in the complex cascade of events leading to the pathology of Alzheimer's disease and several other neurodegenerative disorders. Nevertheless, several aspects of the correlation between the aggregation process and the onset and development of the pathology remain largely elusive. In this context, biophysical and biochemical studies in test tubes have proven extremely powerful in providing quantitative information about the structure and the reactivity of amyloids at the molecular level. In this review we use selected recent examples to illustrate the importance of such biophysical research to complement phenomenological studies based on cellular and molecular biology, and we discuss the implications for pharmaceutical applications associated with Alzheimer's disease and other neurodegenerative disorders in both academic and industrial contexts. |
| doi_str_mv | 10.1007/s11095-017-2266-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1964395226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747438786</galeid><sourcerecordid>A747438786</sourcerecordid><originalsourceid>FETCH-LOGICAL-c228t-959b103c07edc47ef818df2a249b05723c43f6b202eed95f8a6924b2908ddee53</originalsourceid><addsrcrecordid>eNptkE1LxDAQhoMouK7-AG8FD56yTtK0SbzV9WtBUHAFbyVNJ26Wtlmb7kF_vfUD9CDvYeDleWZgCDlmMGMA8iwyBjqjwCTlPM-p2CETlsmUahDPu2QCkguqpGD75CDGNQAopsWELC982KzeoremSYq4QTvEJLikaN5X6FvsT2Ny6SOaiOfJot00Izj40MXEhT55WJm-NRa3w5f_aD12FuMh2XOmiXj0M6fk6fpqOb-ld_c3i3lxRy3naqA60xWD1ILE2gqJTjFVO2640BVkkqdWpC6vOHDEWmdOmVxzUXENqq4Rs3RKTr73bvrwusU4lOuw7bvxZMl0LlKdjb_4pV5Mg6XvXBh6Y1sfbVlIIUWqpPqkZv9QY2psvQ0dOj_2f4QPVQJuUg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1964395226</pqid></control><display><type>article</type><title>Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences</title><source>SpringerLink Journals - AutoHoldings</source><creator>Arosio, Paolo</creator><creatorcontrib>Arosio, Paolo</creatorcontrib><description>An increasing amount of findings suggests that the aggregation of soluble peptides and proteins into amyloid fibrils is a relevant upstream process in the complex cascade of events leading to the pathology of Alzheimer's disease and several other neurodegenerative disorders. Nevertheless, several aspects of the correlation between the aggregation process and the onset and development of the pathology remain largely elusive. In this context, biophysical and biochemical studies in test tubes have proven extremely powerful in providing quantitative information about the structure and the reactivity of amyloids at the molecular level. In this review we use selected recent examples to illustrate the importance of such biophysical research to complement phenomenological studies based on cellular and molecular biology, and we discuss the implications for pharmaceutical applications associated with Alzheimer's disease and other neurodegenerative disorders in both academic and industrial contexts.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-017-2266-4</identifier><language>eng</language><publisher>New York: Springer</publisher><subject>Alzheimer's disease ; Amyloid ; Drug therapy ; Fibrils ; Glycoproteins ; Molecular biology ; Neurodegenerative diseases ; Pathology ; Peptides ; Pharmaceutical sciences ; Pharmaceuticals ; Proteins</subject><ispartof>Pharmaceutical research, 2017-12, Vol.34 (12), p.2628-2636</ispartof><rights>COPYRIGHT 2017 Springer</rights><rights>Pharmaceutical Research is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c228t-959b103c07edc47ef818df2a249b05723c43f6b202eed95f8a6924b2908ddee53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Arosio, Paolo</creatorcontrib><title>Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences</title><title>Pharmaceutical research</title><description>An increasing amount of findings suggests that the aggregation of soluble peptides and proteins into amyloid fibrils is a relevant upstream process in the complex cascade of events leading to the pathology of Alzheimer's disease and several other neurodegenerative disorders. Nevertheless, several aspects of the correlation between the aggregation process and the onset and development of the pathology remain largely elusive. In this context, biophysical and biochemical studies in test tubes have proven extremely powerful in providing quantitative information about the structure and the reactivity of amyloids at the molecular level. In this review we use selected recent examples to illustrate the importance of such biophysical research to complement phenomenological studies based on cellular and molecular biology, and we discuss the implications for pharmaceutical applications associated with Alzheimer's disease and other neurodegenerative disorders in both academic and industrial contexts.</description><subject>Alzheimer's disease</subject><subject>Amyloid</subject><subject>Drug therapy</subject><subject>Fibrils</subject><subject>Glycoproteins</subject><subject>Molecular biology</subject><subject>Neurodegenerative diseases</subject><subject>Pathology</subject><subject>Peptides</subject><subject>Pharmaceutical sciences</subject><subject>Pharmaceuticals</subject><subject>Proteins</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkE1LxDAQhoMouK7-AG8FD56yTtK0SbzV9WtBUHAFbyVNJ26Wtlmb7kF_vfUD9CDvYeDleWZgCDlmMGMA8iwyBjqjwCTlPM-p2CETlsmUahDPu2QCkguqpGD75CDGNQAopsWELC982KzeoremSYq4QTvEJLikaN5X6FvsT2Ny6SOaiOfJot00Izj40MXEhT55WJm-NRa3w5f_aD12FuMh2XOmiXj0M6fk6fpqOb-ld_c3i3lxRy3naqA60xWD1ILE2gqJTjFVO2640BVkkqdWpC6vOHDEWmdOmVxzUXENqq4Rs3RKTr73bvrwusU4lOuw7bvxZMl0LlKdjb_4pV5Mg6XvXBh6Y1sfbVlIIUWqpPqkZv9QY2psvQ0dOj_2f4QPVQJuUg</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Arosio, Paolo</creator><general>Springer</general><general>Springer Nature B.V</general><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20171201</creationdate><title>Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences</title><author>Arosio, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c228t-959b103c07edc47ef818df2a249b05723c43f6b202eed95f8a6924b2908ddee53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer's disease</topic><topic>Amyloid</topic><topic>Drug therapy</topic><topic>Fibrils</topic><topic>Glycoproteins</topic><topic>Molecular biology</topic><topic>Neurodegenerative diseases</topic><topic>Pathology</topic><topic>Peptides</topic><topic>Pharmaceutical sciences</topic><topic>Pharmaceuticals</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arosio, Paolo</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arosio, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences</atitle><jtitle>Pharmaceutical research</jtitle><date>2017-12-01</date><risdate>2017</risdate><volume>34</volume><issue>12</issue><spage>2628</spage><epage>2636</epage><pages>2628-2636</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><abstract>An increasing amount of findings suggests that the aggregation of soluble peptides and proteins into amyloid fibrils is a relevant upstream process in the complex cascade of events leading to the pathology of Alzheimer's disease and several other neurodegenerative disorders. Nevertheless, several aspects of the correlation between the aggregation process and the onset and development of the pathology remain largely elusive. In this context, biophysical and biochemical studies in test tubes have proven extremely powerful in providing quantitative information about the structure and the reactivity of amyloids at the molecular level. In this review we use selected recent examples to illustrate the importance of such biophysical research to complement phenomenological studies based on cellular and molecular biology, and we discuss the implications for pharmaceutical applications associated with Alzheimer's disease and other neurodegenerative disorders in both academic and industrial contexts.</abstract><cop>New York</cop><pub>Springer</pub><doi>10.1007/s11095-017-2266-4</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2017-12, Vol.34 (12), p.2628-2636 |
| issn | 0724-8741 1573-904X |
| language | eng |
| recordid | cdi_proquest_journals_1964395226 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Alzheimer's disease Amyloid Drug therapy Fibrils Glycoproteins Molecular biology Neurodegenerative diseases Pathology Peptides Pharmaceutical sciences Pharmaceuticals Proteins |
| title | Biophysical Aspects of Alzheimer's Disease: Implications for Pharmaceutical Sciences |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A37%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biophysical%20Aspects%20of%20Alzheimer's%20Disease:%20Implications%20for%20Pharmaceutical%20Sciences&rft.jtitle=Pharmaceutical%20research&rft.au=Arosio,%20Paolo&rft.date=2017-12-01&rft.volume=34&rft.issue=12&rft.spage=2628&rft.epage=2636&rft.pages=2628-2636&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-017-2266-4&rft_dat=%3Cgale_proqu%3EA747438786%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1964395226&rft_id=info:pmid/&rft_galeid=A747438786&rfr_iscdi=true |